Intracellular targeting specificity of novel phthalocyanines assessed in a host-parasite model for developing potential photodynamic medicine

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Dutta, Sujoy ^a   Ongarora, Benson G ^b   Li, Hairong ^b   da Vicente, Maria Graca H ^b   Kolli, Bala K ^a   Chang, Kwang Poo ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OVALBUMIN; PHTHALOCYANINE DERIVATIVE; SILICON PHTHALOCYANINE DERIVATIVE; UNCLASSIFIED DRUG; ZINC PHTHALOCYANINE DERIVATIVE; HLA ANTIGEN; INDOLE DERIVATIVE; PHTHALOCYANINE;

ANIMAL CELL; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL VIRULENCE; CD8+ T LYMPHOCYTE; CELL TRANSPORT; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOLYSIS; DENDRITIC CELL; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; ENDOCYTOSIS; HOST PARASITE INTERACTION; HOST RANGE; IN VITRO STUDY; LEISHMANIA; LEISHMANIASIS; MACROPHAGE; MITOCHONDRION; MOUSE; NONHUMAN; PHAGOLYSOSOME; PHOTODYNAMIC THERAPY; PHOTOLYSIS; PHOTOSENSITIVITY; PHOTOTOXICITY; T LYMPHOCYTE ACTIVATION; ANIMAL; CELL LINE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECT; ENZYME SPECIFICITY; IMMUNOLOGY; INTRACELLULAR SPACE; LIGHT; METABOLISM; METHODOLOGY; PARASITOLOGY; PHAGOSOME; PHOTOCHEMOTHERAPY; PHYSIOLOGY; RADIATION EXPOSURE; SOLUBILITY;

PROTOZOA; TRYPANOSOMATIDAE;

ANIMALS; ANTIGEN PRESENTATION; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DENDRITIC CELLS; DRUG DISCOVERY; ENDOCYTOSIS; HLA ANTIGENS; HOST-PARASITE INTERACTIONS; INDOLES; INTRACELLULAR SPACE; LEISHMANIA; LIGHT; MACROPHAGES; MICE; MITOCHONDRIA; OVALBUMIN; PHAGOSOMES; PHOTOCHEMOTHERAPY; PHOTOLYSIS; SOLUBILITY; SUBSTRATE SPECIFICITY;

EID: 79958086748     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020786     Document Type: Article

References (38)

1. Oleinick NL, Evans HH, (1998) The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 150: S146-156.
2. Demidova TN, Hamblin MR, (2004) Photodynamic therapy targeted to pathogens. Int J Immunopathol Pharmacol 17: 245-254.
3. Canti G, Lattuada D, Morelli S, Nicolin A, Cubeddu R, et al. (1995) Efficacy of photodynamic therapy against doxorubicin-resistant murine tumors. Cancer Lett 93: 255-259.
4. Lønning PE, (2010) Molecular basis for therapy resistance. Mol Oncol 4: 284-300.
5. Akilov OE, Kosaka S, O'Riordan K, Song X, Sherwood M, et al. (2006) The role of photosensitizer molecular charge and structure on the efficacy of photodynamic therapy against Leishmania parasites. Chem Biol 13: 839-847.
6. Asilian A, Davami M, (2006) Comparison between the efficacy of photodynamic therapy and topical paromomycin in the treatment of Old World cutaneous leishmaniasis: a placebo-controlled, randomized clinical trial. Clin Exp Dermatol 31: 634-637.
7. Dutta S, Ray D, Kolli BK, Chang KP, (2005) Photodynamic sensitization of Leishmania amazonensis in both extracellular and intracellular stages with aluminum phthalocyanine chloride for photolysis in vitro. Antimicrob Agents Chemother 49: 4474-4484.
8. Enk CD, Fritsch C, Jonas F, Nasereddin A, Ingber A, et al. (2003) Treatment of cutaneous leishmaniasis with photodynamic therapy. Arch Dermatol 139: 432-434.
9. Escobar P, Hernández IP, Rueda CM, Martínez F, Páez E, (2006) Photodynamic activity of aluminium (III) and zinc (II) phthalocyanines in Leishmania promastigotes. Biomedica 26: 49-56.
10. Gardlo K, Horska Z, Enk CD, Rauch L, Megahed M, et al. (2003) Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol 48: 893-896.
11. Gardner DM, Taylor VM, Cedeño DL, Padhee S, Robledo SM, et al. (2010) Association of acenaphthoporphyrins with liposomes for the photodynamic treatment of leishmaniasis. Photochem Photobiol 86: 645-652.
12. González U, Pinart M, Reveiz L, Alvar J, (2008) Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev 8: CD005067.
13. World Health Organization (2010) Leishmaniasis: background information. Available from: http://www.who.int/leishmaniasis/en/index.html. Accessed 2011 May 18.
14. Quellete M, Drummelsmith J, Leprohon P, Fadili KE, Foucher A, et al. (2008) Drug Resistance in Leishmania. In: Myler PJ, Fasel N, editors. Leishmania: After the Genome Norfolf, UK Caister Academic Press pp. 159-176.
15. Alvar J, Croft S, Olliaro P, (2006) Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 61: 223-274.
16. Murray HW, Berman JD, Davies CR, Saravia NG, (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
17. Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28: 7427-7435.
18. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, et al. (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28: 6581-6587.
19. Brandonisio O, Spinelli R, Pepe M, (2004) Dendritic cells in Leishmania infection. Microbes Infect 6: 1402-1409.
20. Chang KP, Fong D, (1983) Cell biology of host-parasite membrane interactions in leishmaniasis. Ciba Found Symp 99: 113-137.
21. Soong L, (2008) Modulation of dendritic cell function by Leishmania parasites. J Immunol 180: 4355-4360.
22. Kumari S, Samant M, Khare P, Misra P, Dutta S, et al. (2009) Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur J Immunol 39: 178-191.
23. Sah JF, Ito H, Kolli BK, Peterson DA, Sassa S, et al. (2002) Genetic rescue of Leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J Biol Chem 277: 14902-14909.
24. Dutta S, Kolli BK, Tang A, Sassa S, Chang KP, (2008) Transgenic Leishmania model for delta-aminolevulinate-inducible monospecific uroporphyria: cytolytic phototoxicity initiated by singlet oxygen-mediated inactivation of proteins and its ablation by endosomal mobilization of cytosolic uroporphyrin. Eukaryot Cell 7: 1146-1157.
25. Porgador A, Yewdell JW, Deng Y, Bennink JR, Germain RN, (1997) Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. Immunity 6: 715-726.
26. Shastri N, Gonzalez F, (1993) Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J Immunol 150: 2724-2736.
27. Mckeown NB, (1998) Phthalocyanine Materials- Synthesis, structure and function UK Cambridge University press.
28. DeRosa MC, Crutchley RJ, (2002) Photosensitized singlet oxygen and its applications. Coord Chem Rev 233: 351-371.
29. Morris RL, Varnes ME, Kenney ME, Li YS, Azizuddin K, et al. (2002) The peripheral benzodiazepine receptor in photodynamic therapy with the phthalocyanine photosensitizer Pc 4. Photochem Photobiol 75: 652-661.
30. Dutta S, Furuyama K, Sassa S, Chang KP, (2008) Leishmania spp.: delta-aminolevulinate-inducible neogenesis of porphyria by genetic complementation of incomplete heme biosynthesis pathway. Exp Parasitol 118: 629-636.
31. Lovell JF, Liu TW, Chen J, Zheng G, (2010) Activatable photosensitizers for imaging and therapy. Chem Rev 110: 2839-2857.
32. Li H, Jensen TJ, Fronczek FR, Vicente MG, (2008) Syntheses and properties of a series of cationic water-soluble phthalocyanines. J Med Chem 51: 502-511.
33. Shen Z, Reznikoff G, Dranoff G, Rock KL, (1997) Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 158: 2723-2730.
34. Castro R, Scott K, Jordan T, Evans B, Craig J, et al. (2006) The ultrastructure of the parasitophorous vacuole formed by Leishmania major. J Parasitol 92: 1162-1170.
35. Dzierszinski F, Pepper M, Stumhofer JS, LaRosa DF, Wilson EH, et al. (2007) Presentation of Toxoplasma gondii antigens via the endogenous major histocompatibility complex class I pathway in nonprofessional and professional antigen-presenting cells. Infect Immun 75: 5200-5209.
36. Liu X, Chang KP, (1994) Identification by extrachromosomal amplification and overexpression of a zeta-crystallin/NADPH-oxidoreductase homologue constitutively expressed in Leishmania spp. Mol Biochem Parasitol 66: 201-210.
37. Mills IG, Jones AT, Clague MJ, (1999) Regulation of endosome fusion. Mol Membr Biol 16: 73-79.
38. Varela MRE, Muñoz DL, Robledo SM, Kolli BK, et al. (2009) Leishmania (Viannia) panamensis: an in vitro assay using the expression of GFP for screening of antileishmanial drug. Exp Parasitol 122: 134-139.